

*Cited in: EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

*Reviews*

**Lung cancer survivors and employment: A systematic review**

F. Vayr, F. Savall, L. Bigay-Game, J.-M. Soulat, C. Chouaid, F. Herin (France) 31

*Original Research Articles*

**Treatment, no treatment and early death in Danish stage I lung cancer patients**

N.L. Christensen, S. Dalton, J. Ravn, J. Christensen, E. Jakobsen, T.R. Rasmussen (Denmark) 1

**Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer**

M. Pérol (France), K.B. Winfree, G. Cuyun Carter, Z. Lin Cui, L. Bowman, E.B. Garon (USA) 6

**Predictive value of a prognostic model based on pathologic features in lung invasive adenocarcinoma**

A. Liu, F. Hou, Y. Qin, G. Song, B. Xie, J. Xu, W. Jiao (China) 14

**Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos**

P. Maisonneuve, C. Rampinelli, R. Bertolotti, A. Misotti, F. Lococo, M. Casiraghi, L. Spaggiari, M. Bellomi, P. Novellis, M. Solinas, E. Dieci, M. Alloisio, L. Fontana, B. Persechino, S. Iavicoli, G. Veronesi (Italy) 23

**Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study**

L. Willén, A. Berglund, S. Bergström, M. Bergqvist, A. Öjdahl-Bodén, G. Wagenius, M. Lambe (Sweden) 40

**Understanding patients' values and preferences regarding early stage lung cancer treatment decision making**

D.R. Sullivan, K.B. Eden, N.F. Dieckmann, S.E. Golden, K.C. Vranas, S.M. Nugent, C.G. Slatore (United States) 47

**Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer**

C. Lin, X. Shi, S. Yang, J. Zhao, Q. He, Y. Jin, X. Yu (China) 62

**Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017**

N. Takano, R. Ariyasu, J. Koyama, T. Sonoda, M. Saiki, Y. Kawashima, T. Oguri, K. Hisakane, K. Uchibori, S. Nishikawa, S. Kitazono, N. Yanagitani, F. Ohyanagi, A. Horiike, A. Gemma, M. Nishio (Japan) 69

**From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC**

P. Bordi, M. Del Re, R. Minari, E. Rofi, S. Buti, G. Restante, A. Squadrilli, S. Crucitta, C. Casartelli, L. Gnetti, C. Azzoni, L. Bottarelli, I. Petrini, A. Cosenza, L. Ferri, E. Rapacchi, R. Danesi, M. Tiseo (Italy) 78

*(Contents continued overleaf)*



<b>The role of adjuvant therapy for atypical bronchopulmonary carcinoids</b> R.E. Wegner, S. Abel, S. Hasan, Z.D. Horne, A. Colonias, B. Weksler, V. Verma (United States)	90
<b>A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project</b> K.M. Kerr (United Kingdom), E. Thunnissen (Netherlands), U. Dafni (Greece), S.P. Finn (Ireland), L. Bubendorf, A. Soltermann (Switzerland), E. Verbeken (Belgium), W. Biernat (Poland), A. Warth (Germany), A. Marchetti (Italy), E.-J.M. Speel (Netherlands), S. Pokharel (USA), A.M. Quinn (United Kingdom), K. Monkhorst (Netherlands), A. Navarro (Spain), L.B. Madsen (Denmark), T. Radonic (Netherlands), J. Wilson (United Kingdom), G. De Luca (Italy), S.G. Gray (Ireland), R. Cheney (USA), S. Savic (Switzerland), M. Martorell (Spain), T. Muley (Germany), P. Baas (Netherlands), P. Meldgaard (Denmark), F. Blackhall (United Kingdom), A.-M. Dingemans (Netherlands), R. Dziadziuszko (Poland), J. Vansteenkiste (Belgium), W. Weder (Switzerland), V. Polydoropoulou (Greece), T. Geiger, R. Kammler, S. Peters, R. Stahel (Switzerland)	95
<b>Significance of Tsukushi in lung cancer</b> T. Yamada, K. Ohta, Y. Motooka, K. Fujino, S. Kudoh, Y. Tenjin, Y. Sato, A. Matsuo, K. Ikeda, M. Suzuki, T. Ito (Japan)	104
<b>FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective</b> A. Quintanal-Villalonga (Spain, United States), S. Molina-Pinelo, P. Yagüe, Á. Marrugal, L. Ojeda-Márquez, R. Suarez, S. Ponce-Aix, A.B. Enguita, A. Carnero, I. Ferrer, L. Paz-Ares (Spain)	112
<b>Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017</b> M. Lattuca-Truc, J.-F. Timsit, M.G. Levra, S. Ruckly, J. Villa, I. Dumas, J. Pinsolle, L. Ferrer, P. Guillem, D. Moro-Sibilot, A.-C. Toffart (France)	122
<b>Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study)</b> H. Akamatsu, Y. Koh, I. Okamoto, D. Fujimoto, A. Bessho, K. Azuma, S. Morita, N. Yamamoto, K. Nakagawa (Japan)	128
<b>A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases</b> K. Yin, Y.-S. Li, M.-M. Zheng, B.-Y. Jiang, W.-F. Li, J.-J. Yang, H.-Y. Tu, Q. Zhou, W.-Z. Zhong, X.-N. Yang, H.-J. Chen, H.-H. Yan, L.-L. Li, Y.-L. Wu, X.-C. Zhang (China)	134
<b>Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma</b> S.M. Lim, J.W. Choi, M.H. Hong, D. Jung, C.Y. Lee, S.Y. Park, H.S. Shim, S. Sheen, K.I. Kwak, D.R. Kang, B.C. Cho, H.R. Kim (Republic of Korea)	139
<b>Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer</b> S.X. Yan, M.M. Qureshi, M. Dyer, M.T. Truong, K.S. Mak (USA)	147
<i>Short Communications</i>	
<b>Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling</b> S.J. Rice, X. Liu, J. Zhang, B. Jia, H. Zheng, C.P. Belani (USA)	58
<b>The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance</b> G.M. O’Kane, G. Liu, T.L. Stockley, M. Shabir, T. Zhang, J.H. Law, L.W. Le, A. Sacher, F.A. Shepherd, P.A. Bradbury, N.B. Leighl (Canada)	86
<i>Correspondence</i>	
<b>Comment on: Synchronous multiple non-small cell lung cancers in an allograft lung recipient</b> C.T. Gan, E. Verschuuren, W. van de Bij, C. Van De Wauwer, M. Erasmus (The Netherlands)	154
<b>Response to comment on: ‘Synchronous multiple non-small cell lung cancers in an allograft lung recipient’</b> J.-L. Pujol, S. Bommart, P. Pujol (France)	155
<i>Corrigenda</i>	
<b>Corrigendum to “Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas” [Lung Cancer 126 (2018) 189–193]</b> S.-Y. Hu, M.-S. Hsieh, H.-H. Hsu, T.-M. Tsai, X.-H. Chiang, K.-C. Tsou, H.-C. Liao, M.-W. Lin, J.-S. Chen (Taiwan)	157